News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Actavis to Vie with Teva Pharmaceutical Industries Limited for Ratiopharm
February 17, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Iceland's Actavis will forgo backing from Swedish buyout firm EQT as it prepares to square off against larger peer Teva (TEVA.TA) in the bidding for generic drug maker Ratiopharm, several people familiar with the auction said.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
Pfizer
MORE ON THIS TOPIC
Gene editing
Lilly Leans Into Hearing Loss in $1.12B+ Gene Editing Pact With Seamless
January 28, 2026
·
2 min read
·
Tristan Manalac
Inflammatory bowel disease
Boehringer Commits up to $1.26B in IBD Pact With China’s Simcere
January 27, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Revolution Knows Its Worth as Merck Backs Off—For Now
January 26, 2026
·
4 min read
·
Annalee Armstrong
Mergers & acquisitions
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
January 26, 2026
·
1 min read
·
Tristan Manalac